Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-02-22 Annual Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AZ - 2021 ESEF Annual report-T01
Annual Report Classification · 100% confidence The document is explicitly titled 'AstraZeneca Annual Report and Form 20-F 2021'. It contains comprehensive sections including a Strategic Report, Corporate Governance, Financial Statements, and Auditor's Report, covering the full fiscal year 2021. This matches the definition of an Annual Report (10-K). FY 2021
2022-02-22 English
Annual Report 2021
Annual Report Classification · 100% confidence The document is the 'AstraZeneca Annual Report and Form 20-F Information 2021'. It contains comprehensive financial statements, management reports, governance information, and audit reports for the fiscal year 2021. It is a full annual report, not an announcement or a summary. FY 2021
2022-02-22 English
Enhertu improves PFS and OS in HER2-low BC
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 2557C' and is dated '21 February 2022'. It contains an announcement about significant clinical trial results ('Enhertu significantly improved both progression-free and overall survival in DESTINY-Breast04 trial') and includes quotes from company executives and detailed scientific/trial information. The presence of the RNS header and the nature of the content (a major corporate/product update) strongly suggest this is a regulatory news service announcement. Since it is a specific, material announcement that is not a full financial report (10-K, IR) or a standard earnings release (ER), and it is clearly distributed via the RNS system, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such material news releases distributed through official channels.
2022-02-21 English
SAPHNELO APPROVED IN EU FOR SLE
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the approval of Saphnelo in the EU for systemic lupus erythematosus (SLE), including clinical trial results, regulatory background, and company information. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing that provides material information about the company and its products but does not fit into other specific categories such as M&A, capital updates, or governance. The length and content indicate it is a substantive regulatory announcement rather than a brief notice or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-02-16 English
Saphnelo approved in EU for SLE
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number' and includes a date stamp typical of regulatory news services. The content announces the European Union approval of a drug, Saphnelo, by AstraZeneca, detailing clinical trial results and future plans. This type of announcement, which disseminates material, non-financial, or general corporate news via an official channel like RNS (Regulatory News Service), fits best under the general regulatory announcement category, especially since it is not a formal financial report (10-K, IR, ER) or a specific corporate action like a dividend or share transaction. Given the structure and source identifier (RNS Number), it is classified as a Regulatory Filing (RNS).
2022-02-16 English
LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed clinical trial results and medical information about the Lynparza drug combination for prostate cancer, including statistical data, trial design, and safety information. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing used by foreign companies to report material information to the SEC. The document is lengthy (15,000 characters) and contains substantive information but is not a financial report or a presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-02-15 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.